Ebastine, a Mast Cell Blocker Improves Sperm Motility in Asthenospermic Infertile Men

Abstract

Introduction: The right treatment of male infertility is relatively costly procedure. So we should sincerer about the treatment procedure to evaluate the role of mast cell blocker ebastin in male infertility for the sake of the wellbeing of our people. The study aims to observe and evaluate the effect of Mast cell (MC) blocker Ebastin in the improvement of sperm motility in asthenospermic infertile male. Methods: This was a longitudinal clinical trial study and was conducted in the Infertility Unit outdoor, Department of obstetrics and gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka. Bangladesh during the period from January 2015 to December 2015. This study was conducted among the male patients and followed Purposive sampling technique. Finally, 334 cases were enrolled in this study. Among the male with abnormal semen parameter 168 patients were Asthenozospermic and 60 patients were combined Oligo-asthenozospermic. Statistical analysis was carried out by using the SPSS 16.0 & MS-Excel2016. Result: From 334 study people we found in group I, mean sperm total mortality was 24.86±12.02% in pretreatment and 34.29±9.35% in post treatment. The difference was statistically significant (p 0.05). Improved sperm motility was 75.4% of asthenozospermic male in ebastin group and 19.3% in placebo group. Which was statistically significant (p 0.05). Conclusion: that sperm motility and rapid progress had significantly improved after three months’ treatment period with Ebastin than Placebo. Therefore, this study suggested that mast cell blocker ebastin can be helpful than placebo to improve the patients’ sperm motility with asthenozoospermia.